Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Further experimentation also suggests that BPC-157 may speed up bone healing in vivo
BPC-157 is not an FDA-approved drug, which means it is not available as a retail prescription product
Transforming growth factor (TGF)- is principally expressed by macrophages and T lymphocytes
Studies showed: Healing acceleration in NSAID-induced gastric ulcers (rat models) Protection against ethanol and stress-induced mucosal damage Effective healing of inflammatory bowel disease lesions in experimental colitis Fistula healing demonstrated in various gastrointestinal models Cardiovascular Research Vascular Injury and Protection Studies Research on component peptides examined effects in various cardiovascular scenarios: Improved healing in vascular anastomosis models Protection against arrhythmias in toxicity models Enhanced angiogenesis and collateral circulation development Potential cardioprotective effects in ischemia-reperfusion models Critical Research Gap: While individual components show promising effects across multiple tissue types, comprehensive studies specifically examining GLOW Blend as a combined formulation remain limited
July 23, 2026: Pharmacy Compounding Advisory Committee meeting The FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23, 2026 to evaluate BPC-157 and TB-500 (free base and acetate forms), along with KPV and MOTs-C
15 Ocular Health BPC-157 has shown significant promise in treating glaucoma, particularly in models where episcleral veins are cauterized, leading to increased intraocular pressure
US$ 26.22
US$ 20.97
US$ 23.03
US$ 25.48
